Clinical and genetic associations with prostacyclin response in pulmonary arterial hypertension.
Ontology highlight
ABSTRACT: Parenteral prostacyclin therapy is the most efficacious pharmacologic treatment for pulmonary arterial hypertension (PAH), but clinical response is variable. We sought to identify clinical, hemodynamic, and genetic associations with response to prostacyclin therapy. We performed a retrospective analysis of patients within a de-identified electronic health record and associated DNA biobank. Patients with PAH and a right heart catheterization (RHC) in the six months before initiation of a parenteral prostacyclin were included. Responders were defined a priori by attainment of World Health Organization (WHO) functional class (FC) 2 or better at the time of repeat RHC within two years. We performed exploratory analyses to identify genomic associations with prostacyclin response. Of 129 patient
SUBMITTER: Halliday SJ
PROVIDER: S-EPMC6134494 | biostudies-literature | 2018 Oct-Dec
REPOSITORIES: biostudies-literature
ACCESS DATA